Status: Recruiting
Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia
This is a prospective, single-center, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of anti-lymphocyte globulin plus herombopag in combination with the reduced dose of cyclophosphamide (hypo-CASH) for severe aplastic anemia.
Participants needed: 75
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Institute of Hematology & Blood Diseases Hospital, ChinaUpdated: Nov 19, 2024Locations: 1
Eligibility criteria
Subject has a diagnosis of naïve severe or very severe aplastic anemia [+4]
Previously received immunosuppressive therapy > 4 weeks [+9]